Orlando Davis
Psychiatry · Baltimore, MDNPI 1477676807
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $94,680 of the $104,256 with a category attached, or 90.8%. Alkermes, Inc. accounts for 94.5% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $63,546 and has fallen 83.4% since, to $10,518 in 2022. Among psychiatry clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $772.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$98K
- Johnson & Johnson$5K
- AbbVie$133
- Neurocrine Biosciences, Inc.$84
- Otsuka America Pharmaceutical, Inc.$58
- Pfizer$52
- plus $129 from 4 others
What the payments were for
- Speaking & faculty fees$94,68091%
- Travel & lodging$6,1026%
- Food & beverage$3,4743%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 95 | $98,495 |
| Johnson & Johnson | 21 | $5,305 |
| AbbVie | 4 | $133 |
| Neurocrine Biosciences, Inc. | 4 | $84 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Pfizer | 1 | $52 |
| Smith+Nephew | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| Sunovion Pharmaceuticals Inc. | 2 | $29 |
| Lundbeck LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$325,017
- ARISTADA INITIO$81,254
- LYBALVI$64,325
- INVEGA SUSTENNA$5,007
- INVEGA TRINZA$5,007
- VRAYLAR$106
How this compares
$104,256 in reported general payments places this provider in the 95th percentile of 851 psychiatry providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $1,975 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Baltimore
- John VaethBaltimore$2.1M
- Scott AaronsonBaltimore$334K
- Robert LehmanBaltimore$140K
- Karen AndersonBaltimore$117K
- Akira SawaBaltimore$69K
- Paul RosenbergBaltimore$66K
- Adam KaplinBaltimore$62K
- Marc FishmanBaltimore$59K
- David NeubauerBaltimore$59K
- Chiadikaobi OnyikeBaltimore$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.